GP40071 + NovoRapid® Penfill®

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes

Conditions

Diabetes, Diabetes Mellitus, Type 1

Trial Timeline

Jun 3, 2019 → Jan 21, 2020

About GP40071 + NovoRapid® Penfill®

GP40071 + NovoRapid® Penfill® is a phase 3 stage product being developed by GEROPHARM for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT04079413. Target conditions include Diabetes, Diabetes Mellitus, Type 1.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04079413Phase 3Completed